ReviewCurrent neurology and neuroscience reports2012
New approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degeneration.
Review in Current neurology and neuroscience reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- A new era in neuropharmacology: assessing the efficacy and safety of novel anti-amyloid and non-amyloid drug targets for Alzheimer's disease.Journal of neurology · 2026Review
- Article
- Pharmacogenetics or predictive genetics? APOE testing blurs the lines.Frontiers in pharmacology · 2025Review
- More evidence for widespread antagonistic pleiotropy in polymorphic disease alleles.Frontiers in genetics · 2024Review
- Validation of the "Perceptions Regarding pRE-Symptomatic Alzheimer's Disease Screening" (PRE-ADS) Questionnaire in the German Population: Attitudes, Motivations, and Barriers to Pre-Symptomatic Dementia Screening.Journal of Alzheimer's disease : JAD · 2024Article
- Attitudes toward pre-symptomatic screening for Alzheimer's dementia in five European countries: a comparison of family members of people with Alzheimer's dementiaFrontiers in genetics · 2023Article
- Geriatricians' Perspectives on the Multiple Dimensions of Utility of Genetic Testing for Alzheimer's Disease: A Qualitative Study.Journal of Alzheimer's disease : JAD · 2022Article
- Genetic Counselling Improves the Molecular Characterisation of Dementing Disorders.Journal of personalized medicine · 2021Review
- Private payer coverage policies for ApoE-e4 genetic testing.Genetics in medicine : official journal of the American College of Medical Genetics · 2021Article
- The Clinical Spectrum of Young Onset Dementia Points to Its Stochastic Origins.Journal of Alzheimer's disease reports · 2021Article
- Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Article
- Ethical issues in neurogenetics.Handbook of clinical neurology · 2018Review
- Managing Ethical Dilemmas in End-Stage Neurodegenerative Diseases.Geriatrics (Basel, Switzerland) · 2017Review
- Clinical Subtypes of Frontotemporal Dementia.American journal of Alzheimer's disease and other dementias · 2015Review
- [Genetics of dementia].Der Nervenarzt · 2015Review
- Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.Neurology · 2015Review
- APOE ε4 influences β-amyloid deposition in primary progressive aphasia and speech apraxia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2014Article
- Diagnosis and management of the patient with suspected dementia in primary care.Drugs & aging · 2013Review
- Genetic testing for early-onset Alzheimer disease.Continuum (Minneapolis, Minn.) · 2013Article
- Impact of genetic counseling and testing in individuals at high risk of familial Alzheimer's disease from Latin America: a non-randomized controlled trial.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The discovery of new autosomal dominant and susceptibility genes for Alzheimer's disease (AD) and frontotemporal degeneration (FTD) is revealing important new information about the neurodegenerative process and the risk for acquiring these diseases. It is becoming increasingly clear that both the mechanisms that drive these diseases and their phenotypes overlap. New technologies will assist access to genetic testing but may increase difficulty with genetic test interpretation. Thus, the process of genetic counseling and testing for these diseases is becoming more complex. This article will review current knowledge on the genetics of AD and FTD and suggest clinical guidelines for helping families to navigate through these complexities. The implications of future discoveries will be offered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.